Emerging data suggest Retatru tide , a dual agonist targeting both incretin and another hormone, appears to provide a significant development for body management . Preliminary patient investigations have demonstrated substantial decreases in visceral fat , possibly outperforming other weight-loss medications . However , more study is required to co